Several EU health, pharma firms in Guyana until Wednesday to scope investment opportunities

Some 13 health and pharmaceutical companies from seven EU member states are in Georgetown this week, as the European Union’s Health and Pharma Investment Mission officially opened on Monday at the Marriott Hotel, Kingston.

The three-day mission, which runs from June 2–4, forms part of the EU’s flagship Global Gateway initiative, designed to foster sustainable investment and deepen ties with strategic partners across the globe. In Guyana, the focus this week is firmly on healthcare and pharmaceuticals.

Organised by the EU Delegation in Guyana, the mission brings European firms face-to-face with key Guyanese stakeholders, offering a platform to forge partnerships and explore commercial opportunities; understand regulatory frameworks and market trends and engage directly with the country’s rapidly expanding health infrastructure.

The agenda features a packed programme of seminars, business meetings, and field visits, offering valuable insight into what is fast becoming one of the most dynamic investment destinations in the region.

EU Ambassador Rene Van Nes and Minister of Health Dr Frank Anthony are both expected to underscore the strategic significance of this collaboration at the opening.

Guyana’s rapid economic ascent has caught the attention of global investors. With a GDP growth rate of 62.3% in 2022 and a projected 37.2% in 2023, the South American nation—bolstered by its burgeoning oil and gas sector—is now actively courting diversified investment to build resilient, future-ready systems.

The healthcare and pharmaceutical sectors, in particular, are being prioritised by the Guyanese government, with incentives such as tax breaks and reduced tariffs offered to manufacturers and suppliers operating locally. Combined with Guyana’s strategic geographic location and expanding healthcare infrastructure, the country presents a compelling case for European firms seeking to establish a regional footprint.

This week’s mission builds on high-level EU-Caribbean engagement. At the CARICOM Heads of Government Conference on February 19, EU Commission President Ursula von der Leyen unveiled a new initiative to support pharmaceutical production in Barbados and Guyana. The programme includes regulatory cooperation, investment support, and education partnerships, with the aim of developing independent pharma value chains in the Caribbean.

A day earlier, President Irfaan Ali announced a visionary plan to position Guyana as a regional biopharmaceutical and healthcare research hub, working in partnership with the EU, Rwanda, and Harvard University. The initiative will focus on vaccine development, oncology, genomic research, AI-driven diagnostics, and the use of Guyana’s biodiversity for medical innovation.

With this mission, the EU is signalling a long-term commitment to Guyana and the Caribbean. It is not just about trade and investment, but about shared growth, knowledge transfer, and sustainable development.